THEY SAID IT! U.S. SENATORS URGE FDA TO FURTHER CRACK DOWN ON BIG PHARMA’S DTC ADVERTISING

Bipartisan Letter Targets Big Pharma’s Misleading Ads That Inflate Costs And Mislead Patients

In case you missed it, U.S. Senators Dick Durbin (D‑IL) and Roger Marshall (R‑KS) submitted a letter to U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on March 31, 2026, urging the Administration to further tighten oversight of Big Pharma’s direct‑to‑consumer (DTC) drug advertising. The letter focuses on the FDA’s long-standing authority to review advertisements before they air, arguing that stronger pre‑clearance is needed to curb the flood of false or misleading claims about prescription medications in DTC advertising.  

“While almost every other country on Earth prohibits DTC drug advertisements, American patients are bombarded with Super Bowl commercials and incessant social media advertisements about specific medications. In many instances, the advertised product is not even approved by FDA, or omits basic safety and side effect information, creating risk for patients. While the agency has yet to exercise its authority… the current landscape and sheer volume of deceptive advertisements necessitate consideration of this gatekeeping tool,” Durbin and Marshall wrote.

The United States is one of only two developed countries that permits DTC advertising for prescription drugs, placing patients at greater risk of misunderstanding how, when, or why to use a medicine as drugmakers downplay key safety risks.

The senators’ call comes after the FDA issued 1,500 warning letters and more than 100 cease and desist letters to pharmaceutical manufacturers last year for deceptive TV spots and social‑media promotions alleging “false and misleading claims” and the “unlawful sale of unapproved and misbranded drugs.” Durbin and Marshall note that many companies simply write off enforcement action as a cost of doing business, acknowledging that the damage to patients and the U.S. health care system is already done by the time an ad is pulled.

At the same time, annual spending on medical marketing has increased from $17.7 billion in 1997, when the FDA officially permitted pharmaceutical DTC advertising, to $32.6 billion in 2025, with 31 percent of the rise in drug spending attributed to DTC advertising.

Last March, CSRxP conducted a study that found American taxpayers lose more than $1.5 billion each year in tax revenue as they increase public spending on medications and pharmaceutical companies write off these marketing expenses to further pad their bottom line.

FDA Commissioner Marty Makary recently wrote an op-ed in The New York Times drawing on his own personal experience as a physician to detail how Big Pharma’s staggering spending on DTC advertising misleads American patients and increases prescription drug spending.

“As a physician, I’ve had patients walk into my office to ask about medicines they saw advertised. Rarely did the patient actually meet clinical criteria for the drug, but sometimes I would learn that they got it anyway from another source,” Makary wrote. “…The ads are also generally limited to expensive medications, not generic or biosimilar alternatives that are orders of magnitude less expensive. The United States leads the world in drug spending. A nonstop bombardment of ads encouraging medications over lifestyle changes is not a path to making America healthy again.”

Last year, Senators Durbin and Marshall introduced the Protecting Patients from Deceptive Drug Ads Act, which would direct the FDA to issue warning letters and financial penalties for deceptive prescription drug ads and mandate drug manufacturers disclose payments to influencers in marketing efforts.

Congress and the Administration should capitalize on elevated attention and scrutiny around Big Pharma’s DTC advertising by advancing market-based solutions to hold brand name drug companies accountable for these aggressive marketing practices that increase costs for patients, taxpayers and the U.S. health care system.

Read more on Big Pharma’s anticompetitive practices and massive spending on direct-to-consumer advertising HERE.

Read CSRxP’s full report on the taxpayer cost of Big Pharma’s DTC advertising HERE.

Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.